Saturday 17 October 2026 Export SILO’s income statement to Excel — free account

Silo Pharma, Inc.

Silo Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $72,100.00, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 73.3% and free cash flow grew 39.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.18 0.02 −1.67%

Follow SILO

Alert me

Market cap: $1.9M
P/E: 0.0×
Fwd P/E: 18.4×
Dividend yield: —
F-score: 4/9
Altman Z: −3.06
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.01

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	2	1	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 1.91

Revenue 0.07

Net Income (4.47)

Free Cash Flow (3.92)

Net Debt (5.23)

Current Ratio 5.36

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E 18.40

P/S ratio 18.00

P/B ratio 0.27

Past 5Y EPS Growth —

This Y EPS Growth —

Next Y EPS Growth —

Next Y revenue growth 1,237.76%

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.19%

10-year low 10-year high

P/B against its own 10 years 0.15%

10-year low 10-year high

EV/FCF against its own 10 years 53.71%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2026	Powerpack
2025	Powerpack
2024	Powerpack
2023	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	8	7	7	5
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	0	0
	8	7	7	6

	2023	2024	2025	Q'26
Payables	1	2	1	0
ST’ Debt	—	—	—	—
Other	—	—	—	1
	1	2	1	1

Compound Annual Growth %

	10y	5y	3y
Sales	—	12.17%	0.00%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	37.55%	(15.20%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	—	—	—	—
’25	0	0	0	0	0
’24	0	0	0	0	0
’23	0	0	0	0	0
’22	0	0	0	0	0
’21	0	0	0	0	0
’19	—	—	0	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(1)	—	—	—
’25	(2)	(1)	(1)	(1)	(5)
’24	(1)	(1)	(1)	(1)	(4)
’23	(1)	(1)	(1)	(1)	(3)
’22	(1)	0	(1)	(1)	(3)
’21	0	(1)	(1)	(1)	(2)
’20	0	0	0	(1)	(1)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(1)	—	—	—
’25	(2)	(1)	(1)	(1)	(5)
’24	(1)	(1)	(1)	(1)	(4)
’23	(1)	(1)	(1)	(1)	(3)
’22	(1)	0	(1)	(1)	(3)
’21	0	(1)	(1)	(1)	(2)
’20	0	0	0	(1)	(1)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.80)	(0.76)	—	—	—
’25	(3.45)	(2.85)	(1.80)	0.00	(7.50)
’24	(4.20)	(4.65)	(3.30)	(6.15)	(17.84)
’23	(4.30)	(4.82)	(3.15)	(5.71)	(17.99)
’22	(4.59)	(4.97)	(7.37)	(8.73)	(25.65)
’21	(0.16)	(0.07)	48.01	(17.27)	30.51
’20	(0.15)	(0.59)	(0.11)	0.16	(0.69)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	187.50	150.00	150.00	255.00	120.00	90.00	2.55	18.24	11.55	4.88	Analyst estimates 2026–2028 Powerpack
	High	825.00	375.00	1,125.00	750.00	450.00	379.50	186.75	59.69	67.50	50.55
People
People	Employees	—	1	1	1	1	2	3	3	3	3
	Revenue/emp, $m	0.00	0.00	0.00	0.04	0.00	0.04	0.02	0.02	0.02	0.02
Income, $m
Income, $m	Revenue	0	—	—	0	—	0	0	0	0	0
	Gross margin, %	100.00	—	0.00	32.51	—	92.99	91.96	91.96	91.96	38.56
	EBT	(1)	0	(1)	(1)	(3)	4	(4)	(4)	(4)	(4)
	EBT margin, %	(2,234.94)	0.00	0.00	(2,495.81)	0.00	5,865.36	(5,419.42)	(5,036.20)	(6,092.79)	(5,863.66)
	Net income	(1)	0	(1)	(1)	(3)	4	(4)	(4)	(4)	(4)
	Depreciation	—	—	0	0	1	0	—	0	0	0
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.03	0.00	0.56	0.47	0.35	0.29	0.13
	Earnings	—	0.11	(0.30)	(0.65)	(0.69)	30.85	(25.65)	(17.99)	(17.84)	(7.50)
	Cash flow	0.00	(0.09)	0.08	(0.51)	(0.26)	(17.99)	(22.95)	(15.70)	(15.62)	(8.34)
	Capex	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	(1.03)
	Free cash flow	0.00	(0.09)	0.08	(0.51)	(0.26)	(17.99)	(22.95)	(15.70)	(15.62)	(9.37)
	Book value	0.00	0.36	0.12	(0.01)	0.29	71.58	67.85	30.07	20.51	11.28
	Shares, m	—	3	3	2	4	0	0	0	0	1
Valuation, ×
Valuation, ×	P/E	0.00	—	—	0.00	—	3.48	0.00	0.00	0.00	0.00
	P/S	0.00	—	—	0.00	—	190.70	97.47	65.04	45.52	39.60
	P/B	0.00	—	—	0.00	—	1.50	0.68	0.76	0.65	0.45
	EV/Sales	0.00	—	—	0.00	—	46.69	(60.40)	(41.37)	(52.77)	(55.61)
	EV/FCF	0.00	—	—	(517.26)	—	(1.46)	1.24	0.92	0.99	0.86
Cash, $m
Cash, $m	Operating cash flow	0	0	0	(1)	(1)	(2)	(3)	(3)	(4)	(5)
	Capex	—	—	—	—	—	—	—	—	—	(1)
	Free cash flow	0	0	0	(1)	(1)	(2)	(3)	(3)	(4)	(5)
Balance, $m
Balance, $m	Working capital	1	2	1	0	1	10	11	7	5	7
	Total debt	—	—	0	0	0	—	—	—	—	—
	Net debt	(1)	(2)	(1)	0	(1)	(10)	(11)	(8)	(7)	(7)
	Shareholders’ equity	1	1	0	0	1	9	10	6	5	6
Returns, %
Returns, %	ROA	(171.28)	24.24	(77.66)	(150.21)	(323.51)	41.95	(35.32)	(38.17)	(57.96)	(56.31)
	ROIC	0.00	0.00	0.00	0.00	(880.40)	0.00	0.00	0.00	0.00	0.00
	ROE	0.00	34.79	(120.40)	(527.07)	(493.96)	48.34	(40.29)	(44.81)	(78.37)	(74.56)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
KAPA Kairos Pharma, Ltd.	$2.3M	— (loss-making)	—	—	n/m	−25.71% (below 0%: shrinking)	—	0.00%	Compare
VRAX Virax Biolabs Group Limited	$2.2M	— (loss-making)	— (loss-making)	—	−855.56% (below 0%: shrinking)	+32.24% (above 0%: growing)	(53.57%)	0.00%	Compare
CLSDQ Clearside Biomedical, Inc.	$2.2M	— (loss-making)	— (loss-making)	−80.64% (below 0%: shrinking)	n/m	+8.15% (above 0%: growing)	100.00%	(3,502.49%)	Compare
BRTX Biorestorative Therapies, Inc.	$2.0M	— (loss-making)	— (loss-making)	−7.20% (below 0%: shrinking)	n/m	−35.26% (below 0%: shrinking)	68.10%	(14,593.53%)	Compare
PPBT Purple Biotech Ltd. Sponsored ADR	$2.0M	— (loss-making)	— (loss-making)	—	n/m	−62.10% (below 0%: shrinking)	0.00%	0.00%	Compare
OGEN Oragenics, Inc.	$2.0M	0.4×	— (loss-making)	−75.33% (below 0%: shrinking)	n/m	−66.37% (below 0%: shrinking)	100.00%	0.00%	Compare
SILO Silo Pharma, Inc.	$1.9M	— (loss-making)	18.4×	0.00%	n/m	+39.17% (above 0%: growing)	(15.00%)	0.00%
GNPX GENPREX	$1.9M	0.0×	—	—	n/m	−32.98% (below 0%: shrinking)	0.00%	0.00%	Compare
TRVN Trevena, Inc.	$1.8M	— (loss-making)	— (loss-making)	+57.22% (above 0%: growing)	n/m	+49.55% (above 0%: growing)	59.72%	(1,970.67%)	Compare
Median of peers	$2.0M	—	—	−41.26%	—	−29.34%	59.72%	0.00%

All 614 Biotechnology stocks →

Silo Pharma, Inc. (SILO) key facts

Silo Pharma, Inc. (SILO) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
Silo Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $72,100.00, roughly unchanged from fiscal 2024.
As of October 16, 2026, SILO traded at $1.18, a market capitalization of $1.9 million.
Return on equity was −74.6% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −3.06 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.